

WEDNESDAY 11th NOVEMBER 2015 COMMENCING 9.30 AM
AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | | |
|-----|--|----------------------------|
| | | Enclosure |
| 1. | Welcome and introduction | |
| 2. | Apologies | |
| 3. | Declarations of interest | |
| 4. | Minutes of previous meeting | 1/AWMSG/1115 |
| 5. | Chairman's report (verbal update) | |
| 6. | Appraisal 1 – Full Submission
Insulin glargine (Abasaglar[®]) for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above | 2/AWMSG/1115
Appendices |
| 7. | Appraisal 2 - Full Submission
Sucroferric oxyhydroxide (Velporo[®]) for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Sucroferric oxyhydroxide (Velporo [®]) should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease | 3/AWMSG/1115
Appendices |
| 8. | Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG – Data to March 2015 | 4/AWMSG/1115 |
| 9. | National Prescribing Indicators 2015–2016 – Analysis of Prescribing Data to June 2015 | 5/AWMSG/1115 |
| 10. | Appraisal 3 - Full Submission
Tedizolid phosphate (Sivextro[®]) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults | 6/AWMSG/1115
Appendices |
| 11. | Appraisal 4 – Limited Submission
Raltegravir (Isentress[®]) in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of 4 weeks | 7/AWMSG/1115
Appendices |

- | | | |
|-----|---|----------------------------|
| 12. | Appraisal 5 – Limited Submission
Adalimumab (Humira®) for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have an inadequate response to or are inappropriate candidates for topical therapy and phototherapies | 8/AWMSG/1115
Appendices |
| 13. | Appraisal 6 – Limited Submission
Tinzaparin sodium (innohep®) for the extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours | 9/AWMSG/1115
Appendices |
| 14. | Feedback from AWPAG Meeting held 23rd September 2015 | 10/AWMSG/1115 |
| 15. | All Wales Policy for Medicines Administration, Recording, Review, Storage and Disposal | 11/AWMSG/1115 |
| 16. | All Wales Guidance for Health Boards/Trusts in Respect of Medicines and Health Care Support Workers | 12/AWMSG/1115 |

To protect commercial confidentiality, the next appraisal will be conducted in private.

- | | | |
|-----|--|-----------------------------|
| 17. | Appraisal 7 – Limited Submission (PAS)
Denosumab (Xgeva®) for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity | 13/AWMSG/1115
Appendices |
|-----|--|-----------------------------|

The meeting will now re-open to the public for the announcement of the committee's decision

**Date of next meeting:
Wednesday 9th December 2015 in Abergavenny**